Clinical efficacy and safety of first-line treatments in patients with mantle cell lymphoma: A systematic literature review.
Immunotherapy
Mantle cell lymphoma
Non-Hodgkin lymphoma
Systematic review
Journal
Critical reviews in oncology/hematology
ISSN: 1879-0461
Titre abrégé: Crit Rev Oncol Hematol
Pays: Netherlands
ID NLM: 8916049
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
05
03
2020
revised:
31
07
2020
accepted:
20
12
2020
pubmed:
1
1
2021
medline:
16
2
2021
entrez:
31
12
2020
Statut:
ppublish
Résumé
Mantle cell lymphoma (MCL) is a rare form of non-Hodgkin's lymphoma (NHL) with a median overall survival (OS) of approximately 3-5 years. Systematic literature reviews (SLRs) identified efficacy and safety data for first-line therapies, reported in randomised controlled trials (RCTs) and non-randomised interventional studies (NRISs). Nine and 20 independent studies were included in the RCT and NRISs SLRs, respectively. Differences in the regimens and patient outcomes varied according to patient age and suitability for autologous stem cell transplantation (ASCT). In elderly patients ineligible for transplant, OS ranged from 40 months to 69.6 months. In young transplant-eligible patients, OS ranged from 53 months to 152.4 months. Despite the paucity of directly comparable evidence on the efficacy and safety of MCL therapies, these SLRs highlight that MCL remains a difficult NHL subtype to treat, with short survival highlighting the unmet need for newer treatments that improve patient outcomes.
Identifiants
pubmed: 33383209
pii: S1040-8428(20)30348-6
doi: 10.1016/j.critrevonc.2020.103212
pii:
doi:
Types de publication
Journal Article
Review
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
103212Informations de copyright
Copyright © 2020. Published by Elsevier B.V.